290 related articles for article (PubMed ID: 22689024)
41. [The second life of daptomycin: analysis of a successful come-back].
Decousser JW; Doucet Populaire F
Med Mal Infect; 2008 Dec; 38 Spec No 2():1-3. PubMed ID: 19185200
[No Abstract] [Full Text] [Related]
42. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
Vikram HR; Havill NL; Koeth LM; Boyce JM
J Clin Microbiol; 2005 Oct; 43(10):5384-7. PubMed ID: 16208025
[TBL] [Abstract][Full Text] [Related]
43. [In vitro activity of daptomycin against strains isolated from diabetic foot ulcers].
Sotto A; Laouini D; Bouziges N; Jourdan N; Richard JL; Lavigne JP
Pathol Biol (Paris); 2010 Feb; 58(1):73-7. PubMed ID: 19875242
[TBL] [Abstract][Full Text] [Related]
44. Current use of daptomycin in cardiac surgery and postoperative intensive care.
Kanzler I; Weis F; Beiras-Fernandez A
Expert Rev Anti Infect Ther; 2013 Mar; 11(3):309-20. PubMed ID: 23458770
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study.
Gonzalez-Ruiz A; Beiras-Fernandez A; Lehmkuhl H; Dohmen PM; Loeffler J; Chaves RL
Int J Antimicrob Agents; 2013 Apr; 41(4):372-8. PubMed ID: 23499225
[TBL] [Abstract][Full Text] [Related]
46. Daptomycin.
Tedesco KL; Rybak MJ
Pharmacotherapy; 2004 Jan; 24(1):41-57. PubMed ID: 14740787
[TBL] [Abstract][Full Text] [Related]
47. [Enterococcus faecalis endocarditis successfully treated with daptomycin].
Bonnet E
Med Mal Infect; 2008 Dec; 38 Spec No 2():4-6. PubMed ID: 19185201
[No Abstract] [Full Text] [Related]
48. [Clinical experience with daptomycin use in Spain. Global findings from EU-CORE database].
Almirante B
Med Clin (Barc); 2010 Dec; 135 Suppl 3():23-8. PubMed ID: 21477701
[TBL] [Abstract][Full Text] [Related]
49. A therapeutic benefit of daptomycin against glycopeptide-resistant gram-positive cocci bloodstream infections under neutropenia.
Matsuda K; Koya J; Toyama K; Ikeda M; Arai S; Nakamura F; Okugawa S; Moriya K; Kurokawa M
J Infect Chemother; 2017 Nov; 23(11):788-790. PubMed ID: 28743428
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.
Hegde SS; Janc JW
Expert Rev Anti Infect Ther; 2014 Dec; 12(12):1463-75. PubMed ID: 25382700
[TBL] [Abstract][Full Text] [Related]
51. Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer?
Tsoulas C; Nathwani D
Int J Antimicrob Agents; 2015 Jul; 46(1):1-7. PubMed ID: 25982913
[TBL] [Abstract][Full Text] [Related]
52. Daptomycin: a review of properties, clinical use, drug delivery and resistance.
Vilhena C; Bettencourt A
Mini Rev Med Chem; 2012 Mar; 12(3):202-9. PubMed ID: 22356191
[TBL] [Abstract][Full Text] [Related]
53. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
Marty FM; Yeh WW; Wennersten CB; Venkataraman L; Albano E; Alyea EP; Gold HS; Baden LR; Pillai SK
J Clin Microbiol; 2006 Feb; 44(2):595-7. PubMed ID: 16455920
[TBL] [Abstract][Full Text] [Related]
54. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
Crandon J; Nicolau DP
Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390
[TBL] [Abstract][Full Text] [Related]
55. Daptomycin treatment in Gram-positive vascular graft infections.
Arnaiz de Las Revillas F; Fernandez-Sampedro M; Arnaiz-García AM; Gutierrez-Cuadra M; Armiñanzas C; Pulitani I; Ponton A; Tascon V; García I; Fariñas MC
Int J Infect Dis; 2018 Mar; 68():69-73. PubMed ID: 29373845
[TBL] [Abstract][Full Text] [Related]
56. Development of daptomycin for gram-positive infections.
Tally FP; DeBruin MF
J Antimicrob Chemother; 2000 Oct; 46(4):523-6. PubMed ID: 11020247
[No Abstract] [Full Text] [Related]
57. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE;
N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701
[TBL] [Abstract][Full Text] [Related]
58. [Daptomycin therapy in patients with bacteremia].
Llinares P; Iribarren JA
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():17-25. PubMed ID: 22541971
[TBL] [Abstract][Full Text] [Related]
59. Serious staphylococcal infections--cyclic lipopeptides: meeting new challenges.
Graninger W
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():1-2. PubMed ID: 18226083
[No Abstract] [Full Text] [Related]
60. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients.
Rolston KV; Kapadia M; Tarrand J; Coyle E; Prince RA
Int J Antimicrob Agents; 2013 Jun; 41(6):516-20. PubMed ID: 23481658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
